155 related articles for article (PubMed ID: 31719523)
1. Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS.
Rautenberg C; Germing U; Pechtel S; Lamers M; Fischermanns C; Jäger P; Geyh S; Haas R; Kobbe G; Schroeder T
Blood Cancer J; 2019 Nov; 9(11):86. PubMed ID: 31719523
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
Rautenberg C; Lauseker M; Kaivers J; Jäger P; Fischermanns C; Pechtel S; Haas R; Kobbe G; Germing U; Schroeder T
Eur J Haematol; 2021 Aug; 107(2):283-292. PubMed ID: 33987857
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C; Ramos F; Puig N; Barragán E; de Paz R; Pedro C; Insunza A; Tormo M; Del Cañizo C; Diez-Campelo M; Xicoy B; Salido E; Sánchez del Real J; Hernández M; Chillón C; Sanz GF; García-Sanz R; San Miguel JF; González M
Ann Hematol; 2012 Dec; 91(12):1887-95. PubMed ID: 22875062
[TBL] [Abstract][Full Text] [Related]
4. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Kobayashi S; Ueda Y; Nannya Y; Shibayama H; Tamura H; Ogata K; Akatsuka Y; Usuki K; Ito Y; Okada M; Suzuki T; Hata T; Matsuda A; Tohyama K; Kakumoto K; Koga D; Mitani K; Naoe T; Sugiyama H; Takaku F
Cancer Biomark; 2016 Mar; 17(1):21-32. PubMed ID: 27062571
[TBL] [Abstract][Full Text] [Related]
7. Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.
Yamauchi T; Matsuda Y; Takai M; Tasaki T; Hosono N; Negoro E; Ikegaya S; Takagi K; Kishi S; Yoshida A; Urasaki Y; Ueda T
Anticancer Res; 2012 Oct; 32(10):4479-83. PubMed ID: 23060576
[TBL] [Abstract][Full Text] [Related]
8. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
[TBL] [Abstract][Full Text] [Related]
9. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
[TBL] [Abstract][Full Text] [Related]
10. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
11. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y; Mizutani C; Nannya Y; Kurokawa M; Kobayashi S; Takeuchi J; Tamura H; Ogata K; Dan K; Shibayama H; Kanakura Y; Niimi K; Sasaki K; Watanabe M; Emi N; Teramura M; Motoji T; Kida M; Usuki K; Takada S; Sakura T; Ito Y; Ohyashiki K; Ogawa H; Suzuki T; Ozawa K; Imai K; Kasai M; Hata T; Miyazaki Y; Morita Y; Kanamaru A; Matsuda A; Tohyama K; Koga D; Tamaki H; Mitani K; Naoe T; Sugiyama H; Takaku F
Leuk Lymphoma; 2013 Jul; 54(7):1450-8. PubMed ID: 23110324
[TBL] [Abstract][Full Text] [Related]
13. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
14. The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.
Ido K; Nakamae M; Koh H; Okamura H; Nanno S; Nishimoto M; Takeoka Y; Hirose A; Nakashima Y; Hashimoto Y; Nakane T; Hino M; Nakamae H
Transplantation; 2019 Oct; 103(10):2201-2210. PubMed ID: 30801534
[TBL] [Abstract][Full Text] [Related]
15. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation.
Israyelyan A; Goldstein L; Tsai W; Aquino L; Forman SJ; Nakamura R; Diamond DJ
Bone Marrow Transplant; 2015 Jan; 50(1):26-33. PubMed ID: 25243629
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.
Tamura H; Dan K; Yokose N; Iwakiri R; Ohta M; Sakamaki H; Tohyama K; Kondo A; Hyodo H; Nakamura K; Yamashita T; Elisseeva OA; Oka Y; Oji Y; Sugiyama H; Ogata K
Leuk Res; 2010 Aug; 34(8):986-90. PubMed ID: 20031209
[TBL] [Abstract][Full Text] [Related]
17. [Changes of WT1 mRNA expression level in patients with myelodysplastic syndromes after hypomethylating agents and its prognostic significance].
Zhang HY; Geng SX; Li MM; Lai PL; Deng CX; Lu ZS; Huang X; Wang YL; Weng JY; Du X
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):417-421. PubMed ID: 31207708
[No Abstract] [Full Text] [Related]
18. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
19. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
[TBL] [Abstract][Full Text] [Related]
20. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression.
Pan L; Ohnishi K; Zhang WJ; Yoshida H; Maksumova L; Muratkhodjaev F; Shigeno K; Nakamura S; Luo JM; Hao HL; Fujisawa S; Naito K; Shinjo K; Takeshita A; Ohno R
Leukemia; 2000 Sep; 14(9):1634-41. PubMed ID: 10995011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
